CEITEC researchers contribute to € 40 million IMI-funded project for better care of patients with hematologic malignancies

The Innovative Medicines Initiative (IMI) has approved HARMONY project that aims to foster more rapid and efficient treatment for patients struggling with blood disorders. Made up of 51 partners from 11 European countries, including 7 multinational pharmaceutical companies, HARMONY project brings together key players in the clinical, academic, patient, HTA (health technology assessment), regulatory, economical, ethical and pharmaceutical fields to create tools for determining treatment options for the individual patients taking into account demographic differences, as well as the needs of the individual patients. Prof. Sarka Pospisilova from CEITEC-MU joint the prestigious public-private partnership with corporations such as NOVARTIS, CELGENE, AMGEN, JPNV – JANSSEN, BAYER, MENARINI or TAKEDA supported with overall project budget of € 40 million. During five years her research group will be involved in integration, analyses and harmonization of Big Data acquiring valuable knowledge across the spectrum of hematologic malignancies. Participation in such important project will greatly help the development of further research lines and new collaborations of Medical Genomics laboratory from CEITEC-MU.